

### Remarks

After entry of this amendment, claims 1-7 and 16-22 are pending, of which claims 3-6, 17, and 19-22 are currently withdrawn. Claims 1 and 4 are amended. No new matter is added by any of the amendments made herewith.

For the Examiner's convenience, it is noted that the two limitations ("H1229 cells" and "FEN1") objected to in the (first) Advisory Action as requiring a new search are not present in the claims submitted herewith. In addition, the amendment (from "cell cycle arrest" to "cell proliferation") that was discussed during the November 29 telephone interview is not present in the claims submitted herewith.

#### *Examiner Interview and 2<sup>nd</sup> Advisory Action*

Applicants thank Examiner Halvorson and the Examiner's Supervisor for the telephone interview that took place on Thursday, November 29. During that interview, the amendments that had been submitted on November 20 were discussed, particularly with regard to whether the Examiner would enter them. The Examiner took the amendments under advisement.

#### *Response*

Applicants thank the Examiner for indicating, at page 3 of the Final Office action mailed March 21, 2007, that "Prior art was not found on a method for identifying a compound that modulates cell cycle arrest, wherein the cell is the transformed cancer cell line A549."

Applicants have amended the claims herewith so they are limited specifically to methods in A549 cells. In view of this amendment, Applicants request the withdrawal of the pending prior art rejections, and particularly the anticipation rejections based on Harrington *et al.* (5,874,283)

With regard to the rejection of claim 2 as allegedly obvious in view of Harrington *et al.* in view of Shibata *et al.* (2002), Applicants incorporate herein and renew the arguments made in the July 20, 2007 Response, to the extent those arguments apply to the claims submitted herewith.

**Conclusion**

In view of Applicants' arguments, and the amendments submitted herewith, it is believed that the subject claims are in condition for allowance. If any concerns remain, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630